Research, development and strategic partnering for the global vaccine industry.
<table>
<thead>
<tr>
<th>Contents</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overview</td>
<td>5</td>
</tr>
<tr>
<td>Scientific Advisory Board</td>
<td>6</td>
</tr>
<tr>
<td>Agenda overview</td>
<td>7</td>
</tr>
<tr>
<td>Day 1 combined</td>
<td>8-9</td>
</tr>
<tr>
<td>Day 2 &amp; 3 of the 18th World Vaccine Congress</td>
<td>10-13</td>
</tr>
<tr>
<td>Day 2 &amp; 3 of the 2nd Immune Profiling World Congress</td>
<td>14-17</td>
</tr>
<tr>
<td>Day 2 &amp; 3 of the 3rd World Veterinary Vaccines Congress</td>
<td>18-21</td>
</tr>
<tr>
<td>Interactive Roundtables</td>
<td>22</td>
</tr>
<tr>
<td>Who attends and Why?</td>
<td>23-24</td>
</tr>
<tr>
<td>Floor plan</td>
<td>25-26</td>
</tr>
<tr>
<td>2017 Sponsors and Exhibitors</td>
<td>27</td>
</tr>
<tr>
<td>Book to Attend</td>
<td>28-30</td>
</tr>
</tbody>
</table>
NEW VACCINE & IMMUNE PROFILING TECHNOLOGY IS CHANGING THE WHOLE INDUSTRY

Make sure you are at the forefront of the vaccines industry. No matter where your interest lies, at the 18th annual World Vaccine Congress, World Veterinary Vaccine Congress and Immune Profiling World Congress, we have content, networking and potential partners for you.

By bringing experts from the whole value chain under one roof, you get to choose the sessions which are the most applicable to help your business plan for the future of vaccine research, development and manufacture.

Take just three days out of the office to meet with 450+ potential customers who need to find solutions to challenges around the commercial and scientific issues in manufacturing, trials, strategy, regulation, veterinary, immune profiling, respiratory, therapeutic and emerging diseases vaccines.

**BIOPROCESSING, DELIVERY AND MANUFACTURING**
Optimize early formulation through to clinical manufacturing, by embracing new techniques and technologies

**THERAPEUTIC**
From new adjuvant technologies to novel immunotherapies, better understand the latest developments in the fast-evolving landscape whether you are interested in cancer and immunotherapy, allergy or chronic infectious diseases.

**INFLUENZA AND RESPIRATORY**
Find ways to improve development of universal influenza, RSV, MERS and TB vaccines

**EMERGING AND RE-EMERGING DISEASES**
Understand the opportunities for your business in reacting to global threats like Zika, Malaria, Dengue and Ebola

**PRE-CLINICAL VALIDATION TO CLINICAL TRIALS**
Assess how to improve your clinical trial performance, from developing novel immunological assays to creating clinical efficacy

**IMMUNE PROFILING**
Discuss how profiling of the immune system using high throughput technologies can aid therapeutic design and treatment strategies in infectious and non-infectious diseases including cancer.

Book early to secure your place, visit terrapinn.com/VaccineEurope17
OUR SCIENTIFIC ADVISORY BOARD

Prof Albert Osterhaus
Director Research Center for Emerging Infections and Zoonoses (RIZ)
University of Veterinary Medicine Hannover

Dr Jeffrey Almond
Former Vice President Discovery Research and Development, Sanofi and Visiting Professor
University of Oxford

Dr Jan Poolman
Head Bacterial Vaccine Discovery and Early Development
Janssen Infectious Diseases and Vaccines

Dr Jerald Sadoff
Senior Advisor Vaccine Development
Janssen Infectious Diseases and Vaccines

Dr Antu Dey
Senior Director, Research & Development
International AIDS Vaccine Initiative (IAVI)

Dr Konrad Stradler
Head of R&D Vaccines
Boehringer Ingelheim

Dr Roy Baynes
Senior Vice President Global Clinical Development and Chief Medical Officer
MSD

Dr Nathalie Garçon
CEO & CSO
BIOASTER

Dr Cyril Gay
Senior National Program Leader, Office of National Programs
USDA

Dr Rino Rappuoli
Chief Scientist
GSK Vaccines

Dr Mahesh Kumar
Vice President, Global Biologics Research
Zoetis

Dr Bernard Vallat
Honorary Director General
Office International Des Epizooties

Book early to secure your place, visit terrapinn.com/VaccineEurope17
2017 AGENDA OVERVIEW

DAY 1
- Human Keynote Plenary
- Streams And Co-Conferences
- Break
- Streams And Co-Conferences

DAY 2
- Human Keynote Plenary
- Roundtables
- Streams And Co-Conferences
- New Vaccine Technology
- Veterinary Congress
- One Health
- Emerging & re-emerging
- Clinical Development in Viral
- Early Development
- Veterinary Congress

DAY 3
- Streams And Co-Conferences
- Immune Profiling Congress
- Bacterial Vaccines & Anti-Microbial Resistance
- Technology Supporting Delivery & Manufacture
- Veterinary Vaccine Congress
- Human Keynote Plenary

Book early to secure your place, visit terrapinn.com/VaccineEurope17
Chair’s opening remarks

OPENING PLENARY DISCUSSION: Creating a new strategy: How does the current global outbreak response system need to change?
- Efforts to develop an international fund to develop vaccines that are of low commercial interest but potentially epidemic-proof to the next emerging disease
- Understanding the legal and regulatory framework for licensure of medical countermeasures during public health emergencies
- How do we know which vaccines to stockpile? Initial efforts in MERS-CoV, Lassa and Nipah viruses
- How should pharma and industry respond to developing low income vaccines?
- What’s the global capacity and how fast can we develop a sustainable supply?

Nathalie Garcon, CEO/CSO, BIOASTER

Respiratory Vaccines Track

Therapeutic Vaccines Track

One Health Workshop

RESPIRATORY VACCINES TRACK

Therapeutic Vaccines Track

One Health Workshop with Discovery and Drivers for Emerging Diseases

10:10 NEW: Speed networking – Break the ice with your peers!
Allowing conference delegates to meet each other for a short space of time and exchange business cards. A unique feature guaranteeing heightened networking for all participants

Chair’s opening remarks

Maternal immunisation: Where do we stand and how do we use vaccines, antivirals and antibodies - What’s the strategy?
- Are we vaccinating mums to protect the young or vaccinating the young to protect the elderly?
- How will we integrate vaccines and other therapeutics to manage maternal immunisation?

Dr Jacqueline Miller
VP Clinical R&D, GSK Vaccines US R&D Center
GSK Vaccines

Richard Hatchett
CEO
CEPI

Dr Marie-Paule Kieny
Assistant Director - General - Health Systems and Innovation
WHO

Dr K. Vijay Raghavan
Secretary, Department of Biotechnology
Ministry of Science and Technology, India

11:40 Chair’s opening remarks

11:45 As more universal flu candidates come to light, what are the clinical development plans?
Dr Ted Ross, Director of Center for Vaccines and Immunology, University of Georgia

12:15 Clinical development of a nasal inactivated influenza vaccine
Dr Anna-Karin Maltais, CSO, Eurocine Vaccines

Why haven’t Alzheimer’s vaccines succeeded yet?
Prof Nikolai Petrovsky, Professor, Flinders University School of Medicine, Director, Vaxine Pty

Dr Salim Mujais, SVP, Therapeutic Area Head Immunology, Transplant, Infectious Disease, CNS and Pain, Astellas Pharma

Dr Jean-Christophe Audonnet, Senior Director, Research Strategy, Key Alliances, Bio R&D, Merial and Coordinator, ZAPI

Dr Bart Haagmans, Working Group Leader, Department of Viroscience, Erasmus M.C., Co-coordinator, ZAPI

View the latest programme and speaker line-up at terrapinn.com/VaccineEurope17
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:45</td>
<td>Assays used for vaccine efficacy studies and correlates of protection for influenza vaccines evaluation</td>
<td>Prof Emanuele Montomoli</td>
<td>How can lessons learned from current immunotherapy approaches in development for HIV help us tackle other chronic diseases? Dr Maja Sommerfelt Granvold, Chief Scientific Officer, Bionor Pharma</td>
</tr>
<tr>
<td>13:00</td>
<td>Oral tablet vaccines for the prevention of norovirus or influenza</td>
<td>Dr Sean Tucker</td>
<td>Virus discovery - new kids on the block with pandemic potential Prof Albert Osterhaus, Director Research Center for Emerging Infections and Zoonoses (RIZ), University of Veterinary Medicine Hannover</td>
</tr>
<tr>
<td>13:15</td>
<td>Networking Lunch &amp; Poster Session</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:45</td>
<td>Progress and potential hurdles for development of a universal flu vaccine</td>
<td>Dr Jerald Sadoff</td>
<td>The Global Virome Project: Bringing an end to pandemics Dr Peter Daszak, President, EcoHealth Alliance</td>
</tr>
<tr>
<td>15:15</td>
<td>The challenge of childhood influenza vaccination in Europe</td>
<td>Dr Ruprecht Schmidt-Ott</td>
<td>Personalized cancer vaccines that target patients-specific mutations Dr Karin Jooss, Chief Scientific Officer, Gritstone Oncology, Inc. Use of vaccination in animals for total epizootic disease eradication and anti-microbial resistance control Dr Joseph Domenech, Consultant, ex World Animal Health Organization (OIE) Chargé de Mission and FAO Head of Animal Head Service</td>
</tr>
<tr>
<td>15:45</td>
<td>Immunogenicity of a plant-derived quadrivalent VLP vaccine in adults and the elderly</td>
<td>Senior representative, Medicago</td>
<td>Data supporting the value of check point inhibitors, AMPLIVANT SLP conjugates and neoantigens in combinational immunotherapy against HPV cancers Willem-Jan Kreberger, COO, ISA pharmaceuticals The role of novel diagnostic methods in protecting both animals and humans</td>
</tr>
<tr>
<td>16:15</td>
<td>Networking Break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:45</td>
<td>Update on the Ph I intranasal RSV vaccine SynGEM</td>
<td>Dr Kees Leenhouts</td>
<td>The rationale of combining biomarkers and checkpoint inhibitors with vaccines and oncolytics Dr Angus Dalgleish, Foundation Chair, Clinical Oncology, Research Director, St George’s University, London New insight and the challenges associated with the prevention and control of Rift Valley fever Dr Osama Ahmed Hassan Ahmed, epidemiologist, Public Health Institute &amp; Umea University</td>
</tr>
<tr>
<td>17:00</td>
<td>Landscape analysis of RSV vaccine development and future implications</td>
<td>Dr Marta Nunes</td>
<td>Oncolytic viruses as immunotherapy - Establishing the legitimacy of oncolytic viruses in cancer therapy Dr Brian R. Champion, CSO, PsiOxus Therapeutics Development of proprietary polysaccharide vaccine adjuvants that meet the needs of humans and animals when concerning Influenza, West Nile and other re-emerged viruses Dr Nikolai Petrovsky, Chairman, Vaxine Pty</td>
</tr>
<tr>
<td>17:15</td>
<td>Update on the development of the recombinant RSV vaccine candidate MVA-BN® RSV</td>
<td>Dr Nathaly Samy</td>
<td></td>
</tr>
<tr>
<td>17:30</td>
<td>Developments and updates on the RSV F RSV Vaccine to protect infants via maternal immunization</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:45</td>
<td>Chair closing remarks of day one followed by Drinks Reception</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
# PLENARY SESSION

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00</td>
<td>Chair’s opening remarks</td>
</tr>
<tr>
<td>09:10</td>
<td><strong>PLENARY DISCUSSION:</strong> Where is the global vaccine industry shifting to for new collaborations? Perspectives from emerging markets and Asia</td>
</tr>
<tr>
<td></td>
<td>- The role of emerging markets in the global supply and demand for vaccines</td>
</tr>
<tr>
<td></td>
<td>- What vaccine technologies and vaccine candidates are favourable?</td>
</tr>
<tr>
<td></td>
<td>- Does it align with other philanthropy organisations?</td>
</tr>
<tr>
<td></td>
<td>- The role of Public-Public Partnerships (P2Ps) in vaccine R&amp;D for poverty related and neglected diseases (PRNDs)</td>
</tr>
<tr>
<td></td>
<td>- Priorities for linking new vaccine development with public health in low and middle income countries</td>
</tr>
</tbody>
</table>

**Speakers:**
- Dr Suresh Jadhav, Executive Director, Serum Institute of India
- Dr K. Vijay Raghavan, Secretary, Department of Biotechnology, Ministry of Science and Technology, India
- Dr David Shao, CFO, YISHENG Biopharma
- Dr Krishna Ella, Founder and Chairman, Bharat Biotech
- Dr Jean Lang, Associate Vice President, R&D Policy, Head, Sanofi Pasteur
- Dr Michael Makanga, Executive Director, European & Developing Countries Clinical Trials Partnership (EDCTP)
- Yves Leurquin, Head, Vaccines Market Access, TakePharmaceuticals International

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:10</td>
<td>Where are we in polio eradication? What are the remaining challenges?</td>
</tr>
<tr>
<td></td>
<td>- How will we maintain a polio-free world</td>
</tr>
<tr>
<td></td>
<td>- Are new/different vaccines required in the post eradication era?</td>
</tr>
</tbody>
</table>

**Speaker:**
- Dr Phil Minor, Deputy Director, Head of Virology, NIBSC & Member of the WHO Advisory Panel on Biological Standardization

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:40</td>
<td>Morning Networking Break</td>
</tr>
<tr>
<td>11:40</td>
<td><strong>Interactive Roundtables</strong></td>
</tr>
<tr>
<td></td>
<td>Choose 2 x 45 min long roundtables for these interactive discussions with like-minded peers tackling the same challenges - for more information go to page 17</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:10</td>
<td>Networking Lunch &amp; Poster Session</td>
</tr>
</tbody>
</table>

### DAY 2 AGENDA

**Emerging & Re-emerging Diseases**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:40</td>
<td>Chair’s opening remarks</td>
</tr>
</tbody>
</table>

**Clinical Development in Viral Vaccines**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:45</td>
<td>How close are we to developing a Zika vaccine and when will more susceptible areas benefit from it?</td>
</tr>
</tbody>
</table>

**Clinical Outcomes in Viral Vaccines**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:45</td>
<td>The challenges of clinical development for emerging infectious diseases - The Example of Ebola</td>
</tr>
<tr>
<td></td>
<td>Dr Melanie Saville, VP, Head of Late Development, Clinical and Medical Affairs, Janssen</td>
</tr>
</tbody>
</table>

**Early Development & Manufacturing**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>

**Biopreparedness and Vaccine Progression**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>

**NEW PLATFORMS AND PROCESS DEVELOPMENT**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:45</td>
<td>Pre- formulation and stability studies in different vaccines - Key considerations</td>
</tr>
<tr>
<td></td>
<td>Dr Florence Arvis, Head of Formulation Unit, Sanofi</td>
</tr>
</tbody>
</table>
15:15 Insights from serum antibody response profiling during a malaria vaccine field trial and after zika virus infection  
Dr John Tan, Senior Scientist, Technology Innovation, Roche Sequencing Solutions

15:15 Vaccines and Viral Challenge Agents - What’s the difference?  
Senior representative, SGS Life Sciences

15:15 Development of a breakthrough vaccine manufacturing platform to radically lower costs increasing affordability and availability in developing countries  
Senior representative, Batavia Biosciences

15:45 Networking Break

16:15 Developing a universal vaccine against emerging mosquito-transmitted diseases and influenza  
Gregory Stoloff, CEO, SEEK

16:30 Ph2a studies for a preventive vaccine against the clade B HIV  
Dr Farshad Guirakhoo, CSO, Geovax

16:45 The rise of RNA vaccines: Practical considerations in bioprocessing and production  
MACIVIVA – Developing cold chain independent virosomal vaccines  
Dr Sylvain Fleury, CSO, Mymetics

16:45 From vaccines research to launch of Dengvaxia and collaborative efforts to create a Zika vaccine  
Dr Jean Lang, Associate Vice President, R&D Projects Global Health, Partnerships & Funding, Sanofi Pasteur

17:00 Implementation of an Ebola virus disease vaccine clinical trial during the Ebola epidemic in Liberia: Design, procedures, and challenges  
Challenges of RSV vaccine development  
Rob Dekker, CMC Team Lead, Janssen Infectious Diseases and Vaccines

17:15 Preventing the pandemic potential of MERS-CoV: Updates on research and clinical development  
Dr James Cummings, Senior Director of Clinical Development, Novavax

17:45 Standardization and development of assays for assessment of influenza vaccines correlates of protection  
Patricia Londono-Hayes, Head R&D Initiatives Europe, Sanofi

17:45 INTERACTIVE PANEL: Accelerated development of vaccine products to human clinical trials - Successes and challenges  
Dr Antu Dey, Senior Director, Research & Development, International AIDS Vaccine Initiative (IAVI)  
Dr Kunal Aggarwal, Head of Technical R&D Programs - R&D Center USA, GSK Vaccines  
Dr Jerald Sadoff, Senior Advisor Vaccine Development, Janssen Infectious Diseases and Vaccines

17:45 Chair’s closing remarks followed by MEET & GREET WITH KEY SPEAKERS in the EXHIBITION HALL

View the latest programme and speaker line-up at terrapinn.com/VaccineEurope17
# Chair’s opening remarks

**Dr Jeffrey Almond**, Former Vice President Discovery Research and Development, Sanofi and Visiting Professor, University of Oxford

**TECHNOLOGY SHOWCASE 1**

Proprietary VLP technology for developing safe and efficacious vaccines against enteroviruses and FMD

**Dr Jane Cardosa**, CSO, Sentinext Therapeutics

**TECHNOLOGY SHOWCASE 2**

Use of MAV-VLP platform for development of vaccines for infectious diseases and cancer

**Dr Farshad Guirakhoo**, CSO, Geovax

**TECHNOLOGY SHOWCASE 3**

Using mAbs for targeted immunotherapy against bacterial infections

**Dr Eszter Nagy**, Co-Founder, Chief Scientific Officer, and Managing Director, Arsanis Biosciences GmbH

**TECHNOLOGY SHOWCASE 4**

Structure-based design to tackle vaccine challenges

**Hans (JPM) Langedijk**, Director Subunit Vaccine Design, Janssen Infectious Diseases and Vaccines

**TECHNOLOGY SHOWCASE 5**

The next generation of conjugate vaccine against *Streptococcus pneumoniae* infection: A novel bioconjugation approach

**Dr Amir Faridmoayer**, Co-Founder & Vice President Discovery, LimmaTech Biologics

**TECHNOLOGY SHOWCASE 6**

Flu pandemic response technologies

**Dr Amir Faridmoayer**, Co-Founder & Vice President Discovery, LimmaTech Biologics

**DAY 3 AGENDA**

**Chair’s opening remarks**

**Dr Jan T Poolman**, Head Bacterial Vaccine Discovery and Early Development, Janssen

**TUBERCULOSIS SYMPOSIUM**

The role of vaccines to combat antibiotic-resistant bacteria - WHO perspective

**Dr Martin Friede**, Group Lead, Transfer of Technology for Health Products, WHO

**TECHNOLOGY SHOWCASE 7**

Comparing progress in RNA vaccines

**Extraintestinal pathogenic *E. coli*: Challenges for vaccine development and clinical progress**

**Dr Jan T Poolman**, Head Bacterial Vaccine Discovery and Early Development, Janssen

**TECHNOLOGY SUPPORTING DELIVERY & MANUFACTURE**

Manufacturing capacity planning for Live Virus Vaccines and its impact on product development priorities

**Dr Trent Carrier**, Vice President - Vaccine Technology and Engineering, Takeda

**TB vaccine candidates in early development**

**Virus safety for viral vaccines and viral vectors**

**Dr Anissa Boumilic-Courtade**, Vaccine Market Lead, EMEA, Merck

**Prevention of relapse after Abx treatment**

**Dr Steve Reed**, Founder, President and Chief Scientific Officer, IDRI

**Viral vectors as vaccine platforms: From immunogenicity to impact**

**Dr Katie Ewer**, Senior Immunologist, Supervisor, Jenner Institute, Oxford University

**Advances in intradermal drug delivery**

**Dr Yotam Levin**, CEO, NanoPass Technologies

**Glen Zimmermann**, Sr. Director, Business Development, Administration Systems, West Pharmaceutical Services

**What’s the future of vaccine manufacturing? Value-driven designs that companies can realistically adapt to and a review of current manufacturing processes**

**View the latest programme and speaker line-up at [terrapinn.com/VaccineEurope17](http://terrapinn.com/VaccineEurope17)**
**TECHNOLOGY SHOWCASE 8**

Clinical update on the *Staphylococcus aureus* multi-antigen vaccine  
*Dr Annaliesa Anderson*, Vice President and CSO Bacterial Vaccines, Pfizer  
Overview of the challenges and opportunities presented by plant-based vaccine manufacturing  
*Dr Vidadi Yusibov*, Executive Director, Fraunhofer USA

**TECHNOLOGY SHOWCASE 9**

The threat GAS as AMR rises and the promise of a vaccine  
*Prof David Goldblatt*, Professor of Vaccinology and Immunology, UCL  
Industry perspective on handling the complex and sometimes undefined regulatory requirements

---

**12:20 Networking Lunch**

---

**PLENARY SESSION**

**13:20 Chair’s opening remarks**

**13:30 Vaccines against antibiotic resistance: The PCV paradigm**

- Using PCVs to reduce antibiotic resistance by reducing the vaccine serotype distribution  
- The significance of reducing antibiotic use in children and consequently rest of the population  
- What needs to be done with the appropriate education of reduced antibiotic abuse  

*Prof Ron Dagan*, Professor of Paediatrics and Infectious Diseases, Paediatric Infectious Disease Unit, Soroka University Medical Center

**14:05 How does our microbiome affect the way we respond to vaccines and its effectiveness in preventing disease?**

- Understand the Microbiome and its interaction with the immune system  
- How to effectively manipulate the microbiome to improve vaccine efficacy  
- Potential opportunities and current challenges  

*Dr Vanessa Harris*, Amsterdam Institute for Global Health and Development, University of Amsterdam

**14:55 PLENARY DISCUSSION: Vaccines don’t protect, vaccination does**

- How much damage is done with the wrong information?  
- The use of vaccines or the failure to do so  
- Why make new vaccines if we have old ones that work but aren’t being used?  
- Paving the way for a framework capable of rapidly delivering reliable data on the benefits and risks of vaccines that are on the market

*Prof Albert Osterhaus*, Director Research Center for Emerging Infections and Zoonoses (RIZ), University of Veterinary Medicine Hannover  
*Dr Norman Begg*, Chief Medical Officer, GSK Biologicals

*More panellists to be confirmed*

**15:40 Chair’s closing remarks and close of Congress**
10:10 Leveraging the potential of the innovative LADD program to develop personalized immunotherapies
- Personalized medicine treatment approach by targeting patient-specific neo-antigens
- Discussing strategy and sharing preclinical and PhI data supporting the clinical development programme for pLADD immunotherapy
- Is a personalised medicine approach the next trend in immunotherapy?

Dr Emmett V. Schmidt MD PhD,
Executive Director, Clinical Research,
Merck Research Laboratories - Oncology

12:10 High-resolution profiling of antibody responses to arrays of peptides
- Applications in vaccines, oncology, autoimmune disorders, antibody discovery

Bradley Garcia,
Strategic Technology Commercialization Leader,
Roche Sequencing Solutions
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 12:25 | **High-throughput sequencing for the T-cell and B-Cell repertoire profiling**  
• Effectively employing high-throughput sequencing for advanced profiling  
• Exploiting computational tools for the profiling of T-cell and B-cells for therapeutic developments |
| 12:40 | **Harnessing T cells to develop an innovative immunotherapy that provide patients with access to a promising new treatment for cancer**  
• Designing and employing MHRA approved adaptive clinical trials. Challenges faced and steps taken to overcome hurdles  
• Next steps and considerations for commercialisation |
| 13:10 | Networking Lunch & Poster Session |
| 14:40 | **Improving the anti-tumour immune response through the use of bi-and trifunctional antibody-cytokine fusion proteins**  
• Designing bi- and trifunctional antibody-fusion proteins with IL-15 and costimulatory members of the B7 and TNF superfamily  
• Sharing research which shows enhanced immune responsiveness in vitro and anti-tumour activity in a mouse model in vivo  
• Discussing mode of action employed  
  
**Dr Dafne Mueller,**  
Group Leader, Institute of Cell Biology and Immunology,  
University of Stuttgart |
| 15:10 | **Accuracy and prediction in antibody repertoire analysis**  
• Novel error and bias correction of antibody repertoire data  
• Combining repertoire analysis with machine learning methods for predicting antigen exposure and specificity  
• Functional screening of antibody repertoires using mammalian surface display technology  
  
**Dr Sai Reddy,**  
Assistant Professor of Biomedical Engineering,  
E.T.H. Zurich |
| 15:45 | Networking Break |
| 16:15 | **Adjuvant profiling and systems analysis of vaccine induced response to enhance correlates of protection of human vaccines**  
• Learn opportunities offered by systems analysis of response to human vaccines and adjuvants to inform rational vaccine development  
• Discussing the significance of new biomarkers in vaccine development  
• Sharing ongoing efforts within EU financed research programmes  
  
**Dr Ali Harandi,**  
Associate Professor, Lab head,  
University of Gothenburg |
| 16:45 | **Patient stratification for immunotherapy: tailoring drug design to molecularly defined cancer patient populations**  
• Developing the first and only anti-PDL1 cancer immunotherapy Tecentriq® (Atezolizumab) approved by the FDA for people with the specific metastatic non-small cell lung cancer  
• The Atezolizumab combination approach to maximise efficacy  
• Challenges faced and lessons learnt  
  
**Dr Jun Wang, MD PhD,**  
Senior Medical Director, Cancer Immunotherapy, Genentech/Roche, Product Development Oncology,  
Cancer Immunotherapy Franchise |
| 17:15 | Chair’s closing remarks followed by **MEET & GREET WITH KEY SPEAKERS** in the **EXHIBITION HALL** |
## DAY 3 AGENDA

### IMMUNE RESPONSE AND BIOMARKERS: B-CELL & T-CELL ANALYSIS

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00</td>
<td>Chair’s opening remarks</td>
<td></td>
</tr>
</tbody>
</table>
| 09:10 | Application of sequential vaccination for educated immune responses             | • Employing single cell transcriptomics and advanced X-50 flow cytometry technologies to illicit an educated immune response within HIV patients  
• Sharing exclusive clinical data  
• Highlighting the wider potential for single cell transcriptomics and X-50 technology within the vaccination field  

*Adrian McDermott, Acting Chief, Immunology Core, Vaccine Research Center, NIAID*

| 09:40 | Accelerating innovation with single-cell RNA genome sequencing                  | • Generating many new insights into complex biological systems, ranging from the diversity of microbial ecosystems to the genomics of human cancer  
• Current state of the field: technical challenges and the he discovery of unexpected new biology  
• Predicting advances in the next few years  

| 10:10 | Developing effective biomarker strategies for advanced clinical development of Immune mobilising monoclonal TCRs against cancer (ImmTACs) | • Sharing updates on the phase I/IIa clinical trials in advanced melanoma  
• Employing a unique biomarker strategy which allows for comprehensive analysis of markers within the tumour as well as the surroundings  
• Enhanced knowledge acquired regarding the biologic mechanisms and response rates  

*Dr David Kringe, Head of Biomarkers, Immunocore Limited*

| 10:40 | Morning Networking Break                                                        |                                                                                                                                                                                                          |
| 11:20 | Harnessing natural bacterial products to develop pioneering and gentle immunotherapy treatments | • The potential to develop drugs from bugs  
• Updates on the IMM-101 and IMM-201 clinical and pre-clinical development programmes  
• Highlighting immune-modulatory mode of mechanism  

*Dr Laura Rosa Brunet, Chief Scientific Officer, Immodulun*

### IMMUNO-ONCOLOGY, CHRONIC & AUTOIMMUNE DISEASE APPROACHES

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:50</td>
<td>ABX196, a promising iNKT agonist to enhance therapeutic efficacy in oncology</td>
<td>Dr Hartmut J. Ehrlich, Chief Executive Officer, ABIVAX</td>
</tr>
</tbody>
</table>
12:20 Networking Lunch

13:20 Engineering 2nd Generation SPEAR™ T-cells to overcome TGF-β-mediated immunosuppression
- NY-ESO SPEAR T-cells show promise in clinical trials for solid and liquid tumours
- Depth and durability of responses may be affected by inhibitory cytokines such as Transforming Growth Factor-β (TGF-β) in the tumour microenvironment
- Preclinical assessment of a dominant negative TGF-β receptor (dnTGFβRII) to make T-cells resistant to the inhibitory effects of TGF-β

*Dr Jo Brewer,*
VP Platform Sciences,
Adaptimmune

13:50 Targeting cancer neoantigens: a promising source of immunogens for cancer immunotherapy
- Employing novel antibodies against immunogenic neoantigens
- Antibody development using a novel platform exploiting immunogenic human tumour antigens
- How to identify tumour specific monoclonal antibodies with anti-tumour activity and target antigens
- Sharing pre-clinical and Phase clinical data in patients

*Philip Arlen,*
President and Chief Executive Officer,
Precision Biologics Inc

14:20 Enabling boosted anti-tumour immunity by use of an immuno-oncology-dedicated adenosine receptor antagonist
- Sharing data updates
- Characterization of a novel Adenosine A2A Receptor antagonist optimized to function in high adenosine concentrations within tumours
- Defining the receptors essential for mediation of the effect of adenosine on immune cells within the tumour microenvironment
- Translational strategy to improve the antitumor efficacy in patients

*Dr Christophe Quéva,*
Chief Scientific Officer,
iTeos Therapeutics SA

14:50 Immunoprofiling of tumour-draining lymph nodes: new targets for early intervention
- Immunoprofiling of lymph nodes draining various tumour types has uncovered different immune suppressive mechanisms at play
- Different combinations of locally applied TLR-ligands and/or immune checkpoint inhibitors should be considered for therapeutic conditioning of lymph nodes draining different tumour types.
- Immune suppression of migratory and resident DC subsets in melanoma sentinel lymph nodes is differentially related to locoregional and distant metastasis.
- Local immune modulation of melanoma-draining lymph nodes by CpG or anti-CTLA4 leads to systemic T-cell immunity and protection against metastatic spread.

*Dr Tanja De Gruijl,*
Professor of Translational Tumor Immunology,
V.U. Medisch Centrum

15:20 Chair’s closing remarks and close of Congress
DAY 2 AGENDA

08:30 Chair’s opening remarks

Nathalie Garcon, CEO/CSO, BIOASTER

08:40 Maternal immunity: Opportunities and challenges within the veterinary landscape

- Discussing its role in vaccination and animal health
- Where do we stand right now? How can this strategy be effectively implemented?
- What hurdles need to be overcome?

Dr Mahesh Kumar, Vice President, Global Biologics Research, Zoetis

09:10 Prevention of food borne diseases through vaccination: challenges and opportunities in the global poultry industry

- Economic impact of Foodborne diseases to the Global Poultry Industry
- Emerging/re-emerging foodborne disease pathogens impacting the Global Poultry Industry
- Prevention of Food borne zoonosis through vaccination of Poultry: Challenges and opportunities

Nandakumar D Reddy, Director, Global Vaccine Research, Elanco

09:40 Disease prevention in relation to animal welfare

- The importance of risk control, identifying current and predicted risks and addressing how these can be minimised effectively
- Discussing the industries role when concerning risk control and assessing how the industry can address the current risk control issue

Rik Koopman, Global Technical Director, MSD Animal Health

10:10 Advancing veterinary vaccine innovation using novel biomarker technology

- Covering vaccine biomarker challenges in the pre-clinical and clinical spaces
- Development of biomarkers for adjuvants
- Steps forward for advancing vaccine biomarker research

11:40 Interactive Roundtables

Choose 2 x 45 min long roundtables for these interactive discussions with like-minded peers tackling the same challenges - for more information go to page 17

13:10 Networking Lunch & Poster Session
Aerosol drug delivery technology for improved veterinary vaccination
- Pitfalls with current vaccination technologies
- Improving animal health, and vaccination efficiency, using high performance aerosol drug delivery technology

Manufacturing within the veterinary industry - The future of where it's going
- The significance of manufacturing quality control for veterinary vaccine development and vaccine efficacy
- New manufacturing technologies to that could potentially be commercially viable, and enable effective and rapid response during outbreaks
- Challenges the veterinary vaccine manufacturing is currently facing and steps to overcome these

Randolph Seidler,
Head of Global Business Development Animal Health, Boehringer Ingelheim

The role of omics in veterinary vaccinology: Opportunities and challenges
- How can we exploit omics technology to advance veterinary innovation?
- Transcriptomics provide markers for potent adjuvants and vaccine efficacy
- Transcriptomics help to identify immunological processes crucial for vaccine-induced immunity

Dr Artur Summerfield,
Professor for Veterinary Immunology, Group Head, Institute of Virology and Immunology

African Swine Fever – Dealing with what is yet to come
- Addressing epidemiology and the increasing risk of its spread across Europe
- Developing vaccines to address ASF – where do we stand?
- Challenges needing to be overcome

Dr Marisa Arias,
Technical Director, EU Reference Laboratory for African swine fever, Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA-CISA)

Chair’s closing remarks followed by MEET & GREET WITH KEY SPEAKERS in the EXHIBITION HALL
DAY 3 AGENDA

09:00 Chair’s opening remarks
Nathalie Garcon, CEO/CSO, BIOASTER

09:10 Developing veterinary vaccines for emerging and re-emerging diseases: gaps and requirements
- Key considerations when launching a veterinary vaccine development programme
- Highlighting the constraints that are enforced by national and European regulatory authorities and provide obstacles to obtaining market authorisation
- Promising areas of development
Dr Catherine Charreyre, Head of Research Projects, Merial

09:40 A transboundary problem: Lumpy Skin Disease (LSD)
- Reviewing the current spread of the disease and the role of the vectors and the environmental factors in the epidemiology of the disease
- Addressing the vital issue of vaccination against lumpy skin disease. Is vaccination the most effective control method?
- How can Europe effectively deal with this re-emerging challenge?
Dr Kris De Clercq, Head of Unit, CODA-CERVA (Veterinary and Agrochemical Research Centre)

10:10 Eradication and effective control methods against peste des petits ruminants
- Development of vaccines against PPRV and improved diagnostic tools for field use
- Analysis of the roles of specific viral and host proteins in viral genome and mRNA synthesis
- Addressing the challenges currently being faced and strategies to overcome these
Dr Arnaud Bataille, Researcher in Virology, CIRAD, Deputy Head, OIE/FAO Reference Laboratory for PPR
          Deputy Head, EU Reference Laboratory for PPR

10:40 Networking Break

11:20 Application of DIVA vaccines to address Bovine Tuberculosis in cattle
- Discussing progress made on optimizing the only potentially available vaccine, Bacille Calmette Guérin (BCG)
- What strategies are there to improve BCG efficacy?
- Highlighting recent advances in DIVA development based on the detection of host cellular immune responses by blood-testing or skin-testing approaches
- What are the next steps necessary in order to accelerate DIVA vaccine development?
Martin Vordermeier, Team Leader, Animal Health and Veterinary Laboratories Agency

11:50 Producing several high efficacy vaccines to combat the re-emerged Blue Tongue Virus disease
- Sharing progressive updates on the rapid response to quickly produce several effective vaccines
- Challenges faced, steps taken to overcome these and thoughts for future emerging disease outbreaks.
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:20</td>
<td>Networking Lunch</td>
</tr>
</tbody>
</table>
| 13:20 | The quest to develop new and improved vaccines for a range of economically important livestock diseases  
- Research and data updates in line with Moredun’s veterinary vaccine research  
- Sharing information on development portfolio for vaccines for a range of endemic diseases, particularly parasitic diseases  
- Case study: Barbervax, a vaccine against Haemonchus gastrointestinal worms in sheep  
  - Dr Richard Mole, Commercialisation Manager, Moredun Research Institute |
| 13:50 | Fast track licensing: Rapid registration of novel vaccine platforms panel  
- Industry and regulatory perspectives  
- Addressing acceleration of the licensing and registration process for new vet tech  
- Hear from a company who has successfully registered a novel vaccine platform through fast track licensing.  
- Discussing current challenges, hurdles faced, challenges overcome and thoughts for future  
  - Dr Rosario Bullido, Head of Veterinary Immunological Medicines Assessment Unit Veterinary Medicines Department, AEMPS  
  - Philippe Migraine, Director Regulatory Affairs, Biologica New Projects, Merial  
  - Additional panelists to be confirmed shortly |
| 14:50 | Increasing availability of veterinary medicinal products through harmonisation of national regulation regarding autogenous farm specific vaccines  
- The need to harmonise requirements and the understanding of “in the same locality”, regarding the concept of epidemiological links between farms  
- Discussing the importance of defining good practices regarding the manufacture and control of autogenous vaccines  
- Considering potential implementation strategies to incorporate harmonisation within legislative framework  
  - Jean de Foucauld, Senior Bio Regulatory Expert, Ceva |
| 15:20 | Harmonisation of registration requirements for veterinary vaccines in East Africa and a regional, time-based Mutual Recognition Procedure  
- Harmonising technical requirements  
- Development of a Mutual Recognition Procedure (MRP)  
- Implementing MRP in the East African Community  
  - Gillian Cowan, Regulatory Affairs Consultant, Global Alliance for Livestock Veterinary Medicines (GALVmed) |
| 15:50 | Chair’s closing remarks and close of Congress                            |

View the latest programme and speaker line-up at [terrapinn.com/VaccineEurope17](http://terrapinn.com/VaccineEurope17)
Choose your roundtable session and explore a range of topical issues that can be discussed with other though leaders at a more interactive basis.

- Incorporating "passive immunization" with vaccines – the use of Phage therapies and mABs
  *Dr Eszter Nagy*, Co-Founder, Chief Scientific Officer, and Managing Director, Arsanis Biosciences GmbH

- Using an autologous vaccine to enhance immunotherapy outcomes and tackle a re-occurring disease within companion animals
  *Dr Patrick Frayssi*, R&D Director, URODELIA

- Porcine T lymphocytes – analysis of their response after vaccination
  *Prof. Dr. Armin Saalmüller*, Institute of Immunology, Department of Pathobiology, University of Veterinary Medicine Vienna

- Vaccines don't protect, vaccination does
  *Prof Albert Osterhaus*, Director Research Center for Emerging Infections and Zoonoses (RIZ), University of Veterinary Medicine Hannover

- Vaccine delivery: How to increase efficacy of vaccines, and the challenges from moving to therapeutic vaccines versus prophylactic
  *Senior representative, 3M*

- The significant role of the microbiome in disease prevention, treatment and therapeutic development
  *Jeff Riley*, CEO, Synthetic Biologics, Inc.

- Successful regulatory use of challenge studies
  *Senior representative, SGS Life Sciences*

- Advanced veterinary therapies: stem cells, monodonal antibodies and bacterial phages for veterinary use
  *Dr Rosario Bullido*, Head of Veterinary Immunological Medicines Assessment Unit, AEMPS

- Porcine T lymphocytes – analysis of their response after vaccination
  *Prof. Dr. Armin Saalmüller*, Institute of Immunology, Department of Pathobiology, University of Veterinary Medicine Vienna

- Vaccines don't protect, vaccination does
  *Prof Albert Osterhaus*, Director Research Center for Emerging Infections and Zoonoses (RIZ), University of Veterinary Medicine Hannover

- Vaccine delivery: How to increase efficacy of vaccines, and the challenges from moving to therapeutic vaccines versus prophylactic
  *Senior representative, 3M*

- The significant role of the microbiome in disease prevention, treatment and therapeutic development
  *Jeff Riley*, CEO, Synthetic Biologics, Inc.

- Successful regulatory use of challenge studies
  *Senior representative, SGS Life Sciences*

- Advanced veterinary therapies: stem cells, monodonal antibodies and bacterial phages for veterinary use
  *Dr Rosario Bullido*, Head of Veterinary Immunological Medicines Assessment Unit, AEMPS

- Porcine T lymphocytes – analysis of their response after vaccination
  *Prof. Dr. Armin Saalmüller*, Institute of Immunology, Department of Pathobiology, University of Veterinary Medicine Vienna

- Vaccines don't protect, vaccination does
  *Prof Albert Osterhaus*, Director Research Center for Emerging Infections and Zoonoses (RIZ), University of Veterinary Medicine Hannover

- Vaccine delivery: How to increase efficacy of vaccines, and the challenges from moving to therapeutic vaccines versus prophylactic
  *Senior representative, 3M*

- The significant role of the microbiome in disease prevention, treatment and therapeutic development
  *Jeff Riley*, CEO, Synthetic Biologics, Inc.

- Successful regulatory use of challenge studies
  *Senior representative, SGS Life Sciences*

- Advanced veterinary therapies: stem cells, monodonal antibodies and bacterial phages for veterinary use
  *Dr Rosario Bullido*, Head of Veterinary Immunological Medicines Assessment Unit, AEMPS

- Porcine T lymphocytes – analysis of their response after vaccination
  *Prof. Dr. Armin Saalmüller*, Institute of Immunology, Department of Pathobiology, University of Veterinary Medicine Vienna

- Vaccines don't protect, vaccination does
  *Prof Albert Osterhaus*, Director Research Center for Emerging Infections and Zoonoses (RIZ), University of Veterinary Medicine Hannover

- Vaccine delivery: How to increase efficacy of vaccines, and the challenges from moving to therapeutic vaccines versus prophylactic
  *Senior representative, 3M*
The 450+ vaccine & immune profiling attendees in 2016 came from

75% end users

325 companies

32 countries

Pharma 25%

Biotech 30%

Government Organization 10%

Non-Profit / Charity 5%

Academia / Research Institutions 10%

Other Supply Chain 20%
HOW WILL OUR SPONSORS & EXHIBITORS BENEFIT?

Over the course of the meeting in Barcelona all the sponsors and exhibitors will benefit from direct F2F access with over 450 delegates, where in total there will be over 8 hours of networking sessions taking place. Different levels of partner involvement and activities offer the following:

PRESENTATIONS

High level sponsors are able to give full speaker case study presentations directly to potential and existing clients reinforcing their credibility and demonstrating thought leadership on specific topic areas.

EXHIBITION

With 30 exhibitors in total in 2016, they all have a unique opportunity to put their business products and services in front of potential buyers looking to source the latest technologies in the industry. This enables our clients to generate a high level of sales leads and form strong new relationships. All the complimentary buffet lunches and refreshments take place in this room, ensuring potential clients are in touching distance at all times when not in the conference.

HOST A ROUNDTABLE

On one of the days sponsors will have the opportunity to host/moderate one of the Roundtables discussions on a topic of their choice for 45 minutes. The session is part of the conference agenda so all attendees will see the topics and choose the tables of most interest to the subject matter, ensuring the sponsor will be in direct F2F discussion with 15-20 of the most relevant attendees at the event. Topic choices are based on a first come first served policy and naturally we won’t be duplicating topic areas, so if you want to guarantee your topic focus area please let us know asap to avoid disappointment.

BRAND AND POSITIONING

Through the associated company logo visibility on our banners and event marketing information on-site, the sponsors and exhibitors in Barcelona will be able to build their brand and positioning within the vaccine industry. This in turn will help them be seen as a leading solutions and service provider to new and existing customers, as well aligning themselves with industry bellwethers.

DRINKS RECEPTION

The drinks networking receptions at the end of each day will offer everyone the chance to unwind and relax in a more informal setting, developing further the business relationships that are initiated during the day. On the 10th October drinks and canapes will take place at an off-site venue, where 11th October drinks will take place within the exhibition room and form part of the “meet and greet” opportunity with some of the key speakers at the event.

NETWORKING MANAGER

As a high level sponsor there is the opportunity to have your own private networking manager for the event, who will work closely with you to facilitate and arrange 1-2-1 business meetings at the event. They will send out the attendee list approx. 4 weeks prior for the sponsor to choose pre-qualified targeted clients, and we will then assist pre-event and on-site for your team to have those meetings in your own reserved private meeting space.

JUBLIA NETWORKING SYSTEM

Jublia is our dedicated online networking tool used at the event by all the attendees, ensuring everyone focuses their time in valuable conversations and meetings with the right people for their business. It will be used at the event to ensure delegates manage their time onsite efficiently, can find attendees who share the same interests, can search for individuals by industry, company or name, can send and receive emails to the people they’d like to get in contact with, and set up their onsite meetings. Delegates are able to target and arrange to meet everyone they want to before the event begins via the on-line portal.

Book early to secure your place, visit terrapinn.com/VaccineEurope17
2017 FLOOR PLAN

Who will you meet?
- Innovators
- Disruptors
- Decision-Makers
- Influencers
- End-users from large and mid-cap vaccine manufacturers
- SME Biotech
- Academic
- Research Institutes
- Government Bodies
- Regulatory Boards
- Industry Solution Providers

This is a prime opportunity for:
- CROs
- CMOs
- Platform Technology Providers
- Fill / Finish
- Finished Dosage
- Platform Technology Providers
- Drug Delivery Providers
- Drug Diagnostic Providers
- Medical Device Manufacturers
- OEM / Equipment Providers
- Logistics Companies

Sponsorship opportunities include:
- Programme presence - from plenary to track sessions
- Exhibition
- Drinks Reception Sponsor
- Sponsor of the Scientific Poster Session
- Networking Break Sponsor
- Lanyard Sponsor
- Wi-Fi Sponsor
- Show Guide Sponsor

--- Book early to secure your place, visit terrapinn.com/VaccineEurope17

Book early to secure your place, visit terrapinn.com/VaccineEurope17 ---
2017 SPONSORS AND EXHIBITORS

Sponsors

EUROCINE Vaccines  SGS  BATAVIA biosciences  EXPRESSION BIOTECHNOLOGIES

IDT  Julius Clinical  BAVARIAN NORD  medicago

Mucosis  VAXART  VISMEDI  MERCK  Roche

Exhibitors

3M  CLINICS  BioLegend  chemometec  eppendorn

Luminex  MYRIAD RBM  pantec biosolutions  Pfansliehl

PROVEPHARM Solutions  TRISKELION  utmb Health  VACCCELL  Vibalogics

Media Partners

Book early to secure your place, visit terrapinn.com/VaccineEurope17
RESERVE YOUR PLACE TODAY

The earlier you book, the more you’ll save.

[link]

BOOK NOW

Register at [link]

Or call +44 (0) 207 092 1210

BRING YOUR TEAM

With three days packed full of great content and networking opportunities, you can’t possibly cover it all alone!

Bring your team and get an extra discount. Call +44 (0) 207 092 1210